MDK and endometrial cancer: MDK inhibition via imatinib mesylate, a tyrosine kinase inhibitor, has been proposed as a mechanism by which the drug reduces endometrial cancer viability, with the addition of medroxyprogesterone acetate contributing to a further drop in both MDK and viability [156].